William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...

French biotech (ABVX) has emerged as the most likely acquisition target among biotechs in 2026, significantly outpacing others, while liver drug developer Madrigal Pharmaceuticals (MDGL) has become ...

TrinScreen HIV order signals renewed strength in global HIV testing market - Company also reports a key milestone of Adjusted EBITDA(1) positive operations in Q3 2025 and expects to achieve strong ...

Abivax ($ABVX), a French biotech firm, has become the top acquisition candidate among biotechs in 2026, according to a Truist ...

Philadelphia has lagged in biotech R&D jobs despite University of Pennsylvania scientists playing a leading role in ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

The US Congress is poised to enact bipartisan legislation that would block some Chinese biotechnology companies from government-funded contracts and authorize the Trump administration to bar US ...

One of the biotech industry’s most esteemed venture capitalists anticipates that, after two years of drought, a wave of drug ...

The U.K. government wants to boost the local life sciences industry, and it hopes to entice American venture capital firms to ...

The expansion will add about one-third more active manufacturing space to Alnylam's production facility in Norton, and it is ...

Biotech Showcase™ returns to San Francisco during J.P. Morgan Healthcare Week, marking its 19 th year as a premier ...